Monday , January 25 2021

Study & # 39; Clinical Risks & # 39; for screening patients with heart condition. And recognizes biomarkers



Researchers at the University of Birmingham have found two biomarkers that can be used to identify heart conditions known as atrial fibrillation in patients who have three & # 39; clinical risks & # 39; Are there.

Atrial fibrillation is the most common heart rhythm disturbance, affecting 1.6 million people in the UK. People with an atrial fibrillation may be aware of a significant heartbeat, while their heart feels that it is intense, dizziness or defeats freely. Sometimes atrial fibrillation does not produce any symptoms and the person who has it is completely unaware that its heart rate is irregular.

Now scientists have identified that patients are at increased risk of atrial fibrillation if they have three & # 39; clinical risks & # 39; It has old age, male and body mass index. Scientists say that scientists can screen their blood by checking their blood and checking whether they have high level of biomarkers – called a secret hormone by heart, called brain naturally peptide (BNP) and is a responsible protein for phosphate plastic . Growth Factor-23 (FGF-23)

This research was conducted by the Institute of Cardiovascular Science at the University of Birmingham College of Medical and Dental Sciences and the Cancer and Genetic Science Institute and has been published today (January 7th). European Heart Journal.

The first author, Dr. Winnie Chua, said: "People with Atrial Fibrillation are more likely to develop blood clots and suffer from stroke. It is important to take Anticocuentant medicines to stop blood clots for them to avoid stroke." Gtc: prefix = & # 39; gtc: mediawiki-xid = The patient has suffered from stroke.

"It is therefore important that patients with risks be tested so that they can start taking anticoagulants to prevent possible life-threatening complications."

Joint first author Yanis Puri added: "An electrocardiogram (ECG) is a test that is used to show patients to act as an ultra-fibrillation in general, to show whether patients function normally to measure the electrical activity of your heart.

"ECG screening is resource-intensive and cumbersome for patients so it is important that appropriate patients are selected for this type of screening.

"We have the potential to use blood tests in community settings in GP settings to ease patient selection for ECG screening in the biologists that we have identified."

So far, most studies for biomarkers in patients with Atrial Fibrillation are based on hypothesis and involve analysis of one or a small selection of blood biomarkers. In this study, scientists analyzed 40 general cardiovascular biomarkers in a group of 638 hospital patients recruited between September 2014 to August 2016.

To get results, scientists associate traditional numerical analysis with completely new and innovative machine learning techniques.

Senior author Dr Larisa Fabriz said: "Research results were surprising. While BNP's already known and widely used in clinical practice biomarkers, the results of the effectiveness of the FGF-23 biomarker were an unexpected and new discovery. FGF-23 is currently only used in research-based environments Taken, but we have shown how to use it in a clinical setting May be value. "

Professor Paulus Kirchhoff, director of Burdheimskull Science University in Birmingham, said, "We hope that, as a result of our findings, many people who have a mood sickness are diagnosed so that any complications can be prevented."

Funding was funded by the University of Birmingham, research was supported by the UK-funded consortium, KHE, led by the University of Battingham University, British Heart Foundation and Ladukk Foundation. This research was done in collaboration with Sandwell and West Birmingham Hospitals NHS Trust, University Hospitals Birmingham NHS Foundation Trust, European Society of Cardiology, German Atrial Fibillation NetWork (AFNET) and Health Data Research UK.

Associate Medical Director at the British Heart Foundation (BHF) Professor Matin Avakir added: "Atrial fibrillation increases the risk of stroke, which is a serious condition that causes 36,000 deaths every year in the UK, but often it is too late. Modern statistical and machine learning methods have been used to analyze data and encourage encouraging evidence Not easy to mix indices that measure is used to predict atrial phaibrilesanani.

"This study can help people with AF to prevent stroke and its catastrophic results and pave the way for their targeted treatment with blood-related drugs."

This research, which started in 2013, is going on and in the next steps will be followed follow-up evaluation of patients admitted in the study to improve the prevention and treatment of Ariel Fibrillation and further improvement.

###

For further information or to arrange an appointment with researchers, please contact Emma McKinney, Communications Manager (Health Sciences), Birmingham University, Email: [email protected] or tel: +44 (0) 121 414 6681, or contact the Press Office Hours at +44 (0) 7789 921 165 or [email protected]

Editor's notes

* Chua et al (2018). & # 39; Data Based Research and Recognition of Blood-Based Biomarkers Circulation with Current Atrial Fibrillation & # 39; European Heart Journal. DOI: 10.1093 / EUROHART / EH 815

* The authors of this research were Winnie Chua, Yannick Parmma, Victor Cardoso, Georgios Gacatos, Samantha Tull, Georgia Nakhlau, Mark Thomas, Dipak Kottecha, Gregory Lip, Paulus Kirchhof and Larissa Fabriz.

* Birmingham University has been ranked among the world's top 100 institutes. Its work delivers Birmingham to people around the world, including researchers, teachers and more than 5,000 international students from more than 150 countries.

Disclaimer: AAS and Yureklert! The news posted on Uracleart is not responsible for the accuracy of the news release! Through the use of Urea Alert system allotting institutions or any information.


Source link